AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

Oncogene

Volumn 31, Issue 45, 2012, Pages 4759-4767

  Li, Y ^a   Hwang, T H ^a   Oseth, L A ^a   Hauge, A ^b   Vessella, R L ^c,d   Schmechel, S C ^b,e   Hirsch, B ^a,b,e   Beckman, K B ^b   Silverstein, K A ^a   Dehm, S M ^a,e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d Puget Sound VA Health Care System   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Androgen receptor variants; AR alternative splicing; Castration resistant; Intragenic rearrangement; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR 3; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL POPULATION; CONTROLLED STUDY; EXON; GENE DELETION; GENE DISRUPTION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENE STRUCTURE; GENE TARGETING; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN SYNTHESIS; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT;

ALTERNATIVE SPLICING; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; EXONS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; HUMANS; INTRONS; MALE; MICE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA STABILITY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84869094406     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.637     Document Type: Article

References (42)

1. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-991.
2. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808. (Pubitemid 350294296)
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261. (Pubitemid 46211563)
4. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007; 4: 236-244.
5. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912-2918.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39. (Pubitemid 38524696)
7. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552-556. (Pubitemid 37026442)
8. Ford 3rd OH, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003; 170: 1817-1821. (Pubitemid 37254935)
9. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormonerefractory prostate cancer. Cancer Res 2001; 61: 3550-3555. (Pubitemid 32694958)
10. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559-565.
11. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-406.
12. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009; 15: 2091-2097.
13. Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, Helin HJ et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81: 1647-1651. (Pubitemid 33144427)
14. Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I et al. Pattern of somatic androgen receptor gene mutations in patients with hormonerefractory prostate cancer. Lab Invest 2002; 82: 1591-1598. (Pubitemid 35332918)
15. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009; 69: 4434-4442.
16. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59: 2511-2515. (Pubitemid 29269089)
17. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-1398.
18. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21: 2673-2678. (Pubitemid 46606310)
19. Thompson J, Hyytinen ER, Haapala K, Rantala I, Helin HJ, Janne OA et al. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab Invest 2003; 83: 1709-1713. (Pubitemid 38018533)
20. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382 -5386. (Pubitemid 20302992)
21. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-448. (Pubitemid 38173980)
22. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
23. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-6415.
24. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011; 71: 1486-1496.
25. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011; 17: 1649-1657.
26. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
27. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-5477.
28. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-2313.
29. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E et al. Ligandindependent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
30. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-2730.
31. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A et al. Constitutively active androgen receptor splice variants expressed in castrationresistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759-16765.
32. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011; 6: e19059.
33. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011; 71: 2108-2117.
34. Tarailo-Graovac M, Chen N. Using RepeatMasker to identify repetitive elements in genomic sequences. Curr Protoc Bioinformatics 2009. Chapter 4: Unit 4 10.
35. Quinlan AR, Clark RA, Sokolova S, Leibowitz ML, Zhang Y, Hurles ME et al. Genome-wide mapping and assembly of structural variant breakpoints in the mouse genome. Genome Res 2010; 20: 623-635.
36. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 2004; 23: 527-533. (Pubitemid 38720602)
37. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
38. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011; 21: 47-55.
39. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003; 55: 239-246. (Pubitemid 36618182)
40. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34: 646-653. (Pubitemid 36875509)
41. Dagvadorj A, Tan SH, Liao Z, Cavalli LR, Haddad BR, Nevalainen MT. Androgenregulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor. Clin Cancer Res 2008; 14: 6062-6072.
42. Gregory CW, Johnson Jr RT, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-2898. (Pubitemid 32691931)